BioSpace News Archive

Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $ 200,001,600.00 M.N., payable to shareholders of record at the close of business on June 7th, 2023.

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and commissions and offering expenses.

American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (“Aires” or the “Company”), a leader in scientifically-proven EMF modulation technology, today announced the results of voting at its 2023 Annual and Special Meeting (“ASM”) of Shareholders held on May 31, 2023.

Clario announced it is joining CancerX - a public-private partnership to act as a national accelerator to boost innovation in the fight against cancer.

Theratechnologies Inc. today announced that the U.S. Food and Drug Administration (FDA) has agreed to the Company’s amended protocol for the Phase 1 clinical trial of sudocetaxel zendusortide, an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin (SORT1) receptor and expedites the internalization and delivery of a cytotoxic payload directly into cancer cells.

Indivior PLC, a leading addiction treatment company, announced that its subsidiary, Indivior Inc., has reached an agreement to resolve the claims brought by the Attorneys General of 41 states and the District of Columbia in the In re Suboxone Antitrust Litigation multi-district litigation.

AESOP Technology, in collaboration with AstraZeneca Taiwan, has unveiled Medigator, an innovative AI software designed to manage immune-related adverse events (irAEs) and enhance the effectiveness of immunotherapy.

Optinose announced that members of its management team will present a company overview and business update at the Jefferies Healthcare Conference on June 9, 2023 at 10:00 a.m. ET.

Phio Pharmaceuticals Corp. announced the closing of its previously announced registered direct offering of 233,646 shares of common stock, at a purchase price of $4.28 per share.

Bridge Biotherapeutics Inc., a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer, fibrosis and inflammation, will present an overview of its pipeline in multiple disease states on Tuesday, June 6 at the 2023 BIO International Convention taking place in Boston June 5-8.